Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017’, provides in depth analysis on Glucagon Like Peptide 2 Receptor (GLP2R) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Gastrointestinal, Metabolic Disorders and Toxicology under development targeting Glucagon Like Peptide 2 Receptor (GLP2R).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)

The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Hanmi Pharmaceuticals Co Ltd

Naia Ltd

Shire Plc

Tasly Pharmaceutical Group Co Ltd

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Glucagon Like Peptide 2 Receptor (GLP2R) Overview 6

Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Assessment 12

Assessment by Mechanism of Action 12

Assessment by Route of Administration 13

Assessment by Molecule Type 15

Glucagon Like Peptide 2 Receptor (GLP2R) Companies Involved in Therapeutics Development 17

Hanmi Pharmaceuticals Co Ltd 17

Naia Ltd 17

Shire Plc 18

Tasly Pharmaceutical Group Co Ltd 18

Zealand Pharma AS 19

Glucagon Like Peptide 2 Receptor (GLP2R) Drug Profiles 20

FE-203799 Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

glepaglutide Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

GXG-8 Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

HM-15910 Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

NB-1002 Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

teduglutide Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ZPGG-23 Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

ZPGG-72 Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Glucagon Like Peptide 2 Receptor (GLP2R) Dormant Products 34

Glucagon Like Peptide 2 Receptor (GLP2R) Product Development Milestones 35

Featured News & Press Releases 35

Jun 19, 2017: Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome 35

Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome 36

Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Pediatric Patients with Short Bowel Syndrome (SBS) 36

May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome 37

Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 38

Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 38

Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 39

Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 39

Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 40

Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions 41

Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 42

Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 42

Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 43

Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 45

Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome 45

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Stage and Route of Administration, H2 2017 14

Number of Products by Stage and Molecule Type, H2 2017 16

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 17

Pipeline by Naia Ltd, H2 2017 17

Pipeline by Shire Plc, H2 2017 18

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 18

Pipeline by Zealand Pharma AS, H2 2017 19

Dormant Projects, H2 2017 34

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Routes of Administration, H2 2017 13

Number of Products by Stage and Routes of Administration, H2 2017 13

Number of Products by Molecule Types, H2 2017 15

Number of Products by Stage and Molecule Types, H2 2017 15

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports